Cargando…

Clinical validation of an optimized multimodal neurocognitive assessment of chronic mild TBI

OBJECTIVE: Previous laboratory‐based studies have shown that neurocognitive eye‐tracking metrics are sensitive to chronic effects of mild traumatic brain injury (mTBI), even in individuals with normal performance on traditional neuropsychological measures. In this study, we sought to replicate and e...

Descripción completa

Detalles Bibliográficos
Autores principales: Ettenhofer, Mark L., Gimbel, Sarah I., Cordero, Evelyn
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7187705/
https://www.ncbi.nlm.nih.gov/pubmed/32207241
http://dx.doi.org/10.1002/acn3.51020
_version_ 1783527213039091712
author Ettenhofer, Mark L.
Gimbel, Sarah I.
Cordero, Evelyn
author_facet Ettenhofer, Mark L.
Gimbel, Sarah I.
Cordero, Evelyn
author_sort Ettenhofer, Mark L.
collection PubMed
description OBJECTIVE: Previous laboratory‐based studies have shown that neurocognitive eye‐tracking metrics are sensitive to chronic effects of mild traumatic brain injury (mTBI), even in individuals with normal performance on traditional neuropsychological measures. In this study, we sought to replicate and extend these findings in a military medical environment. We expected that metrics from the multimodal Fusion n‐Back test would successfully distinguish chronic mTBI participants from controls, particularly eye movement metrics from the more cognitively challenging “1‐Back” subtest. METHODS: We compared performance of participants with chronic mTBI (n = 46) and controls (n = 33) on the Fusion n‐Back test and a battery of conventional neuropsychological tests. Additionally, we examined test reliability and the impact of potential confounds to neurocognitive assessment. RESULTS: Our results supported hypotheses; Fusion 1‐Back metrics were successful in multimodal (saccadic and manual) classification of chronic mTBI versus control. In contrast, conventional neuropsychological measures could not distinguish these groups. Additional findings demonstrated the reliability of Fusion n‐Back test metrics and provided evidence that saccadic metrics are resistant to confounding influences of age, intelligence, and psychiatric symptoms. INTERPRETATION: The Fusion n‐Back test could provide advantages in differential diagnosis for complex brain injury populations. Additionally, the rapid administration of this test could be valuable for screening patients in clinical settings where longer test batteries are not feasible.
format Online
Article
Text
id pubmed-7187705
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-71877052020-04-29 Clinical validation of an optimized multimodal neurocognitive assessment of chronic mild TBI Ettenhofer, Mark L. Gimbel, Sarah I. Cordero, Evelyn Ann Clin Transl Neurol Research Articles OBJECTIVE: Previous laboratory‐based studies have shown that neurocognitive eye‐tracking metrics are sensitive to chronic effects of mild traumatic brain injury (mTBI), even in individuals with normal performance on traditional neuropsychological measures. In this study, we sought to replicate and extend these findings in a military medical environment. We expected that metrics from the multimodal Fusion n‐Back test would successfully distinguish chronic mTBI participants from controls, particularly eye movement metrics from the more cognitively challenging “1‐Back” subtest. METHODS: We compared performance of participants with chronic mTBI (n = 46) and controls (n = 33) on the Fusion n‐Back test and a battery of conventional neuropsychological tests. Additionally, we examined test reliability and the impact of potential confounds to neurocognitive assessment. RESULTS: Our results supported hypotheses; Fusion 1‐Back metrics were successful in multimodal (saccadic and manual) classification of chronic mTBI versus control. In contrast, conventional neuropsychological measures could not distinguish these groups. Additional findings demonstrated the reliability of Fusion n‐Back test metrics and provided evidence that saccadic metrics are resistant to confounding influences of age, intelligence, and psychiatric symptoms. INTERPRETATION: The Fusion n‐Back test could provide advantages in differential diagnosis for complex brain injury populations. Additionally, the rapid administration of this test could be valuable for screening patients in clinical settings where longer test batteries are not feasible. John Wiley and Sons Inc. 2020-03-23 /pmc/articles/PMC7187705/ /pubmed/32207241 http://dx.doi.org/10.1002/acn3.51020 Text en Published 2020. This article is a U.S. Government work and is in the public domain in the USA. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc. on behalf of American Neurological Association This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Articles
Ettenhofer, Mark L.
Gimbel, Sarah I.
Cordero, Evelyn
Clinical validation of an optimized multimodal neurocognitive assessment of chronic mild TBI
title Clinical validation of an optimized multimodal neurocognitive assessment of chronic mild TBI
title_full Clinical validation of an optimized multimodal neurocognitive assessment of chronic mild TBI
title_fullStr Clinical validation of an optimized multimodal neurocognitive assessment of chronic mild TBI
title_full_unstemmed Clinical validation of an optimized multimodal neurocognitive assessment of chronic mild TBI
title_short Clinical validation of an optimized multimodal neurocognitive assessment of chronic mild TBI
title_sort clinical validation of an optimized multimodal neurocognitive assessment of chronic mild tbi
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7187705/
https://www.ncbi.nlm.nih.gov/pubmed/32207241
http://dx.doi.org/10.1002/acn3.51020
work_keys_str_mv AT ettenhofermarkl clinicalvalidationofanoptimizedmultimodalneurocognitiveassessmentofchronicmildtbi
AT gimbelsarahi clinicalvalidationofanoptimizedmultimodalneurocognitiveassessmentofchronicmildtbi
AT corderoevelyn clinicalvalidationofanoptimizedmultimodalneurocognitiveassessmentofchronicmildtbi